Integra LifeSciences (NASDAQ:IART) reported fourth-quarter 2025 results that topped the midpoint of its guidance range, while ...
Integra LifeSciences IART reported upbeat second-quarter earnings and lowered its FY24 guidance below estimates on Monday. Integra Lifesciences posted adjusted earnings of 63 cents per share, beating ...
StockStory.org on MSN
Why Integra LifeSciences (IART) shares are sliding today
What Happened? Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell 5.7% in the afternoon session after ...
Medical device company Integra LifeSciences (NASDAQ:IART) announced better-than-expected revenue in Q4 CY2025, but sales fell by 1.7% year on year to $434.9 million. On the other hand, next quarter’s ...
In a June 21 hiring announcement, the Princeton-based life sciences company said Daniels Knight brings more than 30 years’ experience to the role. “Lea brings a wealth of finance, accounting, and ...
Medical device company Integra LifeSciences (NASDAQ:IART) in Q3 CY2025, but sales rose 5.6% year on year to $402.1 million. Next quarter’s revenue guidance of $430 million underwhelmed, coming in 5.9% ...
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (IART) (Nasdaq: IART), a leading global medical technology company, commends the Centers for Medicare & ...
In recent trading, shares of Integra LifeSciences Holdings Corp (Symbol: IART) have crossed above the average analyst 12-month target price of $26.00, changing hands for $26.05/share. When a stock ...
Integra LifeSciences Holdings Corp. is seeking to establish itself in the ear, nose and throat category with its acquisition of Acclarent Inc. The Princeton-based medical technology company announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results